Theriva Biologics Inc (TOVX)
2.08
+0.09
(+4.52%)
USD |
NYAM |
Nov 04, 16:00
1.94
-0.14
(-6.73%)
After-Hours: 20:00
Theriva Biologics Research and Development Expense (TTM): 14.61M for June 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2024 | 14.61M |
| March 31, 2024 | 14.79M |
| December 31, 2023 | 14.31M |
| September 30, 2023 | 13.19M |
| June 30, 2023 | 11.75M |
| March 31, 2023 | 12.10M |
| December 31, 2022 | 11.72M |
| September 30, 2022 | 11.43M |
| June 30, 2022 | 10.83M |
| March 31, 2022 | 9.28M |
| December 31, 2021 | 7.801M |
| September 30, 2021 | 6.001M |
| June 30, 2021 | 4.943M |
| March 31, 2021 | 4.614M |
| December 31, 2020 | 5.131M |
| September 30, 2020 | 6.079M |
| June 30, 2020 | 9.309M |
| March 31, 2020 | 10.30M |
| December 31, 2019 | 11.08M |
| September 30, 2019 | 11.21M |
| June 30, 2019 | 9.914M |
| March 31, 2019 | 10.89M |
| December 31, 2018 | 11.84M |
| September 30, 2018 | 13.54M |
| June 30, 2018 | 14.84M |
| Date | Value |
|---|---|
| March 31, 2018 | 16.09M |
| December 31, 2017 | 18.78M |
| September 30, 2017 | 21.76M |
| June 30, 2017 | 24.68M |
| March 31, 2017 | 27.01M |
| December 31, 2016 | 29.11M |
| September 30, 2016 | 31.24M |
| June 30, 2016 | 34.22M |
| March 31, 2016 | 34.57M |
| December 31, 2015 | 32.91M |
| September 30, 2015 | 29.29M |
| June 30, 2015 | 22.94M |
| March 31, 2015 | 18.27M |
| December 31, 2014 | 14.49M |
| September 30, 2014 | 11.96M |
| June 30, 2014 | 9.74M |
| March 31, 2014 | 8.106M |
| December 31, 2013 | 6.507M |
| September 30, 2013 | 14.39M |
| June 30, 2013 | 13.68M |
| March 31, 2013 | 13.02M |
| December 31, 2012 | 12.29M |
| September 30, 2012 | 4.235M |
| June 30, 2012 | 3.761M |
| March 31, 2012 | 3.495M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
4.614M
Minimum
Mar 2021
14.79M
Maximum
Mar 2024
9.963M
Average
10.83M
Median
Jun 2022
Research and Development Expense (TTM) Benchmarks
| BioCardia Inc | 5.069M |
| NovaBay Pharmaceuticals Inc | 0.043M |
| Palatin Technologies Inc | 22.40M |
| iBio Inc | 5.185M |
| Oragenics Inc | 13.38M |